ADVFN - Advanced Financial Network.
HOME» NYSE » F » FRX Stock Price » FRX Stock News

Forest Labs Share News

 Forest Laboratories, Inc. Stock Price
FRX Stock Price
 Forest Laboratories, Inc. Stock Chart
FRX Stock Chart
 Forest Laboratories, Inc. Stock News
FRX Stock News
 Forest Laboratories, Inc. Company Information
FRX Company Information
 Forest Laboratories, Inc. Stock Trades
FRX Stock Trades

Teva Receives FDA Approval For Generic Lexapro For Adults

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) has received U.S. Food and Drug Administration approval to market the first generic version of Forest Laboratories Inc.'s (FRX) Lexapro for adults. The generic drug--escitalopram--is approved to treat depression and generalized anxiety disorder. The world's biggest manufacturer of generic drugs said Wednesday it has been granted a 180-day period of generic-drug exclusivity, which means the FDA can't approve another generic version of escitalopram tablets before the end of that period. Teva, which has diversified into brand-name and over-the-counter drugs, in February expected sales growth for its U.S. generics business to outpace market growth during 2012. Lexapro has been Forest Labs's main money maker. The company in January reported Lexapro sales of $593 million for its fiscal third quarter. Teva last month reported that its fourth-quarter profit declined 34%, as higher acquisition-related costs more than offset a revenue increase fueled by last year's purchase of Cephalon Inc. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stock News for Forest Labs (FRX)
DateTimeHeadline
04/05/201509:52:02Can This Pharma Go From Good to Great?
07/15/201406:07:50Termination of Registration of a Class of Security Under Section...
07/10/201415:59:05Amended Statement of Ownership (sc 13g/a)
07/08/201405:59:41Notice of Effectiveness (effect)

Forest Labs and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad